Evidence map›Paper›PMID 40985774›Full record

ArticleNucleic acids research2025

Engineering of BZ transposase and transposon donor vector for enhanced efficiency and safety in gene delivery applications.

Saisai Wang, Pingjing Zhang, Yan Sun, Yuan Fang, Pei Wang, Meiqi Shao, Ningning Zhang, Shasha Shi, Xin Chen, Haixia Gao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Saisai WangLab of Transposon, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China.
Pingjing ZhangBiological Therapy Center, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China.
Yan SunBiological Therapy Center, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China.
Yuan FangNucleic Acid Research Center, Shanghai Cell Therapy Group Co., Ltd, Shanghai 201805, China.
Pei WangNucleic Acid Research Center, Shanghai Cell Therapy Group Co., Ltd, Shanghai 201805, China.
Meiqi ShaoNucleic Acid Research Center, Shanghai Cell Therapy Group Co., Ltd, Shanghai 201805, China.
Ningning ZhangNucleic Acid Research Center, Shanghai Cell Therapy Group Co., Ltd, Shanghai 201805, China.
Shasha ShiLab of Transposon, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China.
Xin ChenLab of Transposon, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China.
Haixia GaoNucleic Acid Research Center, Shanghai Cell Therapy Group Co., Ltd, Shanghai 201805, China.
Jingbo ChengNucleic Acid Research Center, Shanghai Cell Therapy Group Co., Ltd, Shanghai 201805, China.
Bo GaoLab of Transposon, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China.
Tao LiuBiological Therapy Center, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China.
Qijun QianBiological Therapy Center, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai 201805, China.
Chengyi SongLab of Transposon, College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China.ORCID 0000-0002-0488-4718

Funding

Cell and Gene Therapy ProjectNational Natural Science Foundation of China 32271508Science and Technology Commission of Shanghai Municipality 23J21900500Shanghai Science and Technology Innovation Action Plan
6 · The paper itself

Abstract

Transposons, as non-viral vectors, provide an efficient and secure method for stable gene delivery and have been successfully applied in human gene therapies. The engineering of transposase has significantly improved the efficiency of various transposon systems, including chimeric antigen receptor (CAR)-T cell engineering. In this study, multiple engineering strategies were implemented to enhance the efficiency and safety of the Baize (BZ) transposon system, which was derived from the ZB (the wild-type BZ, BZwt) and has been proven to be an effective tool for genetic manipulation in vertebrates. Through designed engineering and combinatorial mutagenesis in vitro, several hyperactive BZ transposase variants with higher transposition activity, cargo capacity, and integration safety were developed. At optimal activity levels, BZ325 surpassed BZwt by ∼1.2-fold and 2.3-fold at 500 ng and 10 ng dosages of donor plasmids, respectively. Furthermore, reducing the size of BZ donor vector backbone significantly increased CAR-T modification efficiency without compromising its function. Notably, BZ325, BZ326, and especially BZ327 exhibited significantly higher CAR-T engineering rates and CAR expression levels than BZwt. Overall, the engineering of the BZ transposon system significantly enhanced its transposition activity, cargo capacity, and safety, providing a compelling tool for gene transfer applications and emphasizing its potential in gene therapy.

Indexed as

DNA Transposable ElementsGenetic VectorsGene Transfer TechniquesTransposasesAnimalsGenetic EngineeringGenetic TherapyHEK293 CellsHumansPlasmidsProtein EngineeringReceptors, Chimeric AntigenDNA Transposable ElementsReceptors, Chimeric AntigenTransposases

Identifiers

PMID40985774
PMCPMC12455594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.